Abstract: Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Abstract: The present disclosure relates to a transfer cart suitable for use in association with an MR scanner. The transfer cart may include a transfer table assembly coupled to the support frame such that the transfer table assembly and the horizontal support structure portion of the support frame extend substantially perpendicularly from the vertical support structure of the support frame and in substantially parallel planes to each other. The transfer table assembly may be maintained at substantially the same vertical level of a scanning bore of an MR scanner. The transfer cart may include a frame designed to dock with the MR scanner.
Abstract: One aspect of the present disclosure include a method of utilizing an oro-motor device to activate an audio device, the method includes providing an oro-motor device having a sensor and a nipple; producing a signal when the nipple portion present in an infants mouth when the nipple portion yields a first measured pressure over an age appropriate predetermined threshold applied to the nipple portion by the infant; responsive to the signal, playing an age appropriate audio recording for a predetermined duration on an audio device; and raising the age appropriate predetermined threshold to a raised threshold proportionally to a difference between the first measured pressure application to the nipple portion and the age appropriate predetermined threshold.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
November 7, 2023
Assignee:
The Research Institute at Nationwide Children's Hospital
Abstract: In accordance with the present invention, a method for increasing the yield of rLV vector particles comprising a trans gene encoding a therapeutic protein or fragment thereof is disclosed. In one approach, cells are transfected with plasmids encoding the necessary components for rLV production using a calcium chloride transfection mix at pH 7.1 wherein the calcium chloride and plasmids form a complex which is added to the cells at a constant speed. The cells are then incubated for a suitable time period wherein virus particle media is collected at least twice during the incubation period and stored in a cold storage unit, thereby reducing virus inactivation.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
November 7, 2023
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Katherine A. High, John Fraser Wright, Bernd Hauck, Guang Qu
Abstract: Methods and apparatuses for applying tensile force to one or more tissue regions within a body. Illustratively, an implant ball including a spherical side wall is received within a tubular organ, and tensile sutures extend through the implant ball for applying a tensile force to facilitate elongation of the tubular organ.
Abstract: The current disclosure provides chimeric antigen receptors (CARs) that bind a natural killer (NK) cell surface marker, resulting in destruction of the bound NK cell. The NK cell surface markers include an activating NK cell receptor, and an inhibitory NK cell receptor. Cells that are genetically modified to express these CARs and uses of the CAR modified cells are also described.
Type:
Application
Filed:
May 7, 2021
Publication date:
November 2, 2023
Applicant:
Seattle Children's Hospital d/b/a Seattle Children's Research Institute
Abstract: Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Provided herein are viral vectors each comprising a modified capsid, wherein the modified capsid comprises at least one amino acid sequence that targets the viral vector to a distinct brain structure.
Type:
Application
Filed:
November 20, 2020
Publication date:
November 2, 2023
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Beverly DAVIDSON, Yonghong CHEN, Paul T. RANUM, Xueyuan LIU
Abstract: The present invention relates to RNA interference-based methods for inhibiting the expression of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
October 31, 2023
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Inventors:
Scott Quenton Harper, Jian Liu, Sara Coppens, Lindsay Wallace
Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
October 31, 2023
Assignee:
Children's Hospital & Research Center at Oakland
Abstract: Provided herein are chimeric minigenes, where the alternative splicing of the minigene determines whether an encoded gene is expressed. In particular, the minigenes are alternatively spliced in response to splicing modulator dmgs, such that the encoded gene is only expressed in the present of the splicing modulator dmg. The encoded gene may encode an inhibitory RNA, a CRISPR-Cas9 protein, a transactivator, or a therapeutic protein.
Type:
Application
Filed:
February 12, 2021
Publication date:
October 26, 2023
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Beverly L. DAVIDSON, Alejandro Mas MONTEYS, Amiel A. HUNDLEY, Paul T. RANUM
Abstract: A method for k-space registration is provided. The method of k-space registration includes receiving a first partial k-space dataset for an object and a second partial k-space dataset for the object, selecting the first partial k-space dataset as a reference, selecting feature for estimating a transformation matrix for transforming k-space data, estimating a transformation matrix based on the feature of entire or part of the first partial k-space dataset and the feature of the second partial k-space dataset corresponding to the entire or part of the first partial k-space dataset, correcting the second partial k-space dataset based on the transformation matrix, and obtaining the corrected second partial k-space dataset. The present method is further used for partial Fourier reconstruction.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
October 24, 2023
Assignees:
University of Cincinnati, Children's Hospital Medical Center
Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
Type:
Application
Filed:
August 20, 2021
Publication date:
October 19, 2023
Applicants:
The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
Inventors:
Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
Abstract: A system for guiding a medical intervention is disclosed. The system employs a device guide that operates on the surface of a sphere that is centered on a selected target.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
October 17, 2023
Assignee:
Children's Hospital Medical Center
Inventors:
Charles Lucian Dumoulin, Neil David Johnson, Ronald Gene Pratt
Abstract: The use of inhibitors upstream of mTOR in the CSF1 pathway of neuroinflammation, inhibitors of chemokine receptor CXCR3, functional derivatives thereof, and/or immunosuppressant drugs to reduce neuroinflammation are disclosed. The inhibitors and/or immunosuppressant drugs can treat genetic or environmental encephalopathies and/or reduce microglial activation. Treated encephalopathies include Leigh Syndrome and Wernicke encephalopathy.
Type:
Application
Filed:
August 20, 2021
Publication date:
October 12, 2023
Applicant:
Seattle Children's Hospital d/b/a Seattle Children's Research Institute
Inventors:
Simon C. Johnson, Julia Claire Stokes, Rebecca Lois Bornstein, Margaret Mary Sedensky, Philip G. Morgan, Russell P. Saneto
Abstract: Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.
Type:
Application
Filed:
February 1, 2023
Publication date:
October 12, 2023
Applicants:
Texas Children's Hospital, Baylor College of Medicine
Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.
Abstract: This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).
Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
Type:
Grant
Filed:
January 22, 2019
Date of Patent:
October 10, 2023
Assignees:
Endocyte, Inc., Purdue Research Foundation, Seattle Children's Hospital
Inventors:
Philip Stewart Low, Haiyan Chu, Yingjuan June Lu, Christopher Paul Leamon, Leroy W. Wheeler, II, Michael C. Jensen, James Matthaei
Abstract: Disclosed herein are methods for the treatment of an individual having an inflammatory bowel disease (“IBD”). The disclosed methods may include the detection of Oncostatin M (OSM) in a biological sample obtained from an individual having an IBD. The detection of OSM may be used to characterize the individual as a tumor necrosis factor (TNF) inhibitor (TNFi) responder or a TNFi non-responder for selection of appropriate treatment.